BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 27993089)

  • 1. Immunotherapy of colorectal cancer: new perspectives after a long path.
    Correale P; Botta C; Ciliberto D; Pastina P; Ingargiola R; Zappavigna S; Tassone P; Pirtoli L; Caraglia M; Tagliaferri P
    Immunotherapy; 2016 Nov; 8(11):1281-1292. PubMed ID: 27993089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.
    Correale P; Cusi MG; Micheli L; Nencini C; Del Vecchio MT; Torino F; Aquino A; Bonmassar E; Francini G; Giorgi G
    Invest New Drugs; 2006 Mar; 24(2):99-110. PubMed ID: 16502353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy as an Option for Cancer Treatment.
    Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of immunotherapy to treat colorectal cancer.
    Amin M; Lockhart AC
    Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
    Cheng F; Loscalzo J
    Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel vaccines for glioblastoma: clinical update and perspective.
    Winograd EK; Ciesielski MJ; Fenstermaker RA
    Immunotherapy; 2016 Nov; 8(11):1293-1308. PubMed ID: 27993092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and opportunities for immune therapeutics in osteosarcoma.
    Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
    Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
    Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
    Fecek RJ; Storkus WJ
    Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
    Sun L; Chen L; Li H
    Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current opinion on optimal treatment for colorectal cancer.
    Price TJ; Segelov E; Burge M; Haller DG; Ackland SP; Tebbutt NC; Karapetis CS; Pavlakis N; Sobrero AF; Cunningham D; Shapiro JD
    Expert Rev Anticancer Ther; 2013 May; 13(5):597-611. PubMed ID: 23617351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of cancers comes of age.
    Yousefi H; Yuan J; Keshavarz-Fathi M; Murphy JF; Rezaei N
    Expert Rev Clin Immunol; 2017 Oct; 13(10):1001-1015. PubMed ID: 28795649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
    Smith D; Bosacki C; Merrouche Y
    Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
    Grenier JM; Yeung ST; Khanna KM
    Front Immunol; 2018; 9():610. PubMed ID: 29623082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Griffiths R; Steven N; Hawkins RE
    Cancer Immunol Immunother; 2008 Jul; 57(7):977-86. PubMed ID: 18060404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy for colorectal cancer].
    Tougeron D; Fauquembergue É; Latouche JB
    Bull Cancer; 2013 Sep; 100(9):871-85. PubMed ID: 23917703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First- and second-line therapy of metastatic colorectal cancer.
    Terstriep S; Grothey A
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.